Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 716 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cystic Fibrosis Lung Clear all
Completed Not applicable Interventional

Saline Hypertonic in Preschoolers

NCT02378467
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS)
Drug
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 5 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings

NCT00685035
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
HFCWC with higher pressure/variable-frequency settings, HFCWC with lower pressure/mid-frequency settings
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of Linezolid in Children With Cystic Fibrosis

NCT00625703
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Linezolid
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

NCT03140527
View directory record Official record
Conditions
Healthy Volunteer, Cystic Fibrosis
Interventions
PTI-801, Placebo, PTI-808
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

NCT00630812
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled mannitol, Placebo comparator
Drug
Lead sponsor
Syntara
Industry
Eligibility
6 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
28
States / cities
Tucson, Arizona • Hartford, Connecticut • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

NCT06299696
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 19, 2026, 10:43 PM EDT
Completed No phase listed Observational

Tissue Bank for Pulmonary Diseases

NCT00546962
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Recruiting Phase 2 Interventional

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

NCT06747858
View directory record Official record
Conditions
Cystic Fibrosis, CFTR Gene Mutation
Interventions
ARCT-032
Biological
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Enrolling by invitation No phase listed Observational

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

NCT06262282
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions
mycobacteriophage
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Not applicable Interventional Results available

Lung Transplant READY Pilot Study

NCT05135156
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Investigator-designed lung transplant education resource (Research Intervention), Publicly available transplant education resource (Attention Control)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects

NCT02134353
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled mannitol, Placebo Comparator: Arm B - Control
Drug
Lead sponsor
Syntara
Industry
Eligibility
18 Years to 99 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease

NCT00659529
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
sildenafil
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
14 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Not applicable Interventional

Oral Glucose Tolerance Testing Using Candy for Cystic Fibrosis

NCT04579939
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Candy Glucose Tolerance Test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
10 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 19, 2026, 10:43 PM EDT
Recruiting No phase listed Observational

Health Outcomes of Parents With Cystic Fibrosis-Aim 2

NCT06296394
View directory record Official record
Conditions
Cystic Fibrosis, Parenthood Status
Interventions
Parenthood
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Denver, Colorado • Evanston, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Not applicable Interventional Results available

Effect of Chronic Incretin-based Therapy in Cystic Fibrosis

NCT01879228
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Not applicable Interventional Results available

Exploring Novel Interventions to Improve Adherence in Children With Cystic Fibrosis

NCT02301377
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Spiro PD personal spirometer
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 4 Interventional Results available

Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

NCT02421120
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation, Pseudomonas Aeruginosa Infection
Interventions
Ceftolozane/Tazobactam
Drug
Lead sponsor
Joseph L. Kuti, PharmD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Hartford, Connecticut • Indianapolis, Indiana • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)

NCT00082238
View directory record Official record
Conditions
Cystic Fibrosis, Diabetes Mellitus
Interventions
Stable isotopes
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

NCT02354859
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Gallium nitrate, Normal Saline
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of Ataluren (PTC124) in Cystic Fibrosis

NCT01140451
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional

Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

NCT00794586
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
FTI, AZLI, Placebo, AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2013 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

NCT01614457
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Birmingham, Alabama • Palo Alto, California • Hartford, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 1 Interventional

Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

NCT02275936
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
N91115
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 19, 2026, 10:43 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

NCT04135495
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX-02, Ivacaftor
Drug
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Long Beach, California • Palo Alto, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 19, 2026, 10:43 PM EDT